Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s disease

[1]  A. Mirelman,et al.  Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers , 2022, NPJ Parkinson's disease.

[2]  Zhentao Zhang,et al.  Cofilin 1 promotes the pathogenicity and transmission of pathological α-synuclein in mouse models of Parkinson’s disease , 2022 .

[3]  Xiangshui Meng,et al.  Substantia Nigra Radiomics Feature Extraction of Parkinson’s Disease Based on Magnitude Images of Susceptibility-Weighted Imaging , 2021, Frontiers in Neuroscience.

[4]  A. Mirelman,et al.  The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44. , 2021, Molecular genetics and metabolism.

[5]  S. Lehéricy,et al.  Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker , 2021, Movement disorders : official journal of the Movement Disorder Society.

[6]  Ying Wang,et al.  Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease , 2021, NeuroImage.

[7]  Minming Zhang,et al.  An Integrative Nomogram for Identifying Early-Stage Parkinson's Disease Using Non-motor Symptoms and White Matter-Based Radiomics Biomarkers From Whole-Brain MRI , 2020, Frontiers in Aging Neuroscience.

[8]  S. Lehéricy,et al.  Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. , 2020, Brain : a journal of neurology.

[9]  A Ibrahim,et al.  Radiomics for precision medicine: current challenges,future prospects, and the proposal of a new framework. , 2020, Methods.

[10]  C. B. Sanz-Morère,et al.  Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.

[11]  J. Biggio,et al.  Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction: (Replaces Clinical Guideline Number 3, April 2012). , 2020 .

[12]  Yu Liu,et al.  Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence , 2020, NeuroImage.

[13]  J. Biggio,et al.  Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and Management of Fetal Growth Restriction. , 2020, American journal of obstetrics and gynecology.

[14]  J. Aasly,et al.  Clinical and Imaging Markers of Prodromal Parkinson's Disease , 2020, Frontiers in Neurology.

[15]  A. Mirelman,et al.  A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[16]  P. Péran,et al.  Quantitative MRI markers in Parkinson's disease and parkinsonian syndromes. , 2020, Current opinion in neurology.

[17]  Yen F. Tai,et al.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study , 2020, The Lancet Neurology.

[18]  Yanghua Fan,et al.  Application of Radiomics in Central Nervous System Diseases: a Systematic literature review , 2019, Clinical Neurology and Neurosurgery.

[19]  A. Mirelman,et al.  Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk? , 2019, Molecular genetics and metabolism.

[20]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[21]  Y. Shimo,et al.  Neuromelanin or DaT‐SPECT: which is the better marker for discriminating advanced Parkinson's disease? , 2019, European journal of neurology.

[22]  E. Haacke,et al.  Regional High Iron in the Substantia Nigra Differentiates Parkinson’s Disease Patients From Healthy Controls , 2019, Front. Aging Neurosci..

[23]  Yi Wang,et al.  3D texture analyses within the substantia nigra of Parkinson's disease patients on quantitative susceptibility maps and R2∗ maps , 2019, NeuroImage.

[24]  Shanmughavel Piramanayagam,et al.  Impact of gene mutation in the development of Parkinson's disease , 2019, Genes & diseases.

[25]  Anissa Abi-Dargham,et al.  Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain , 2019, Proceedings of the National Academy of Sciences.

[26]  K. Nichols,et al.  Interpreting 123I–ioflupane dopamine transporter scans using hybrid scores , 2018, European Journal of Hybrid Imaging.

[27]  Yen F. Tai,et al.  Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism , 2018, Movement disorders clinical practice.

[28]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[29]  A. Rahmim,et al.  Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images , 2017, NeuroImage: Clinical.

[30]  Tadeusz Sarna,et al.  Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease , 2017, Progress in Neurobiology.

[31]  M. Zappia,et al.  Iron and Parkinson's disease: A systematic review and meta-analysis. , 2017, Molecular medicine reports.

[32]  T. Hendler,et al.  DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers , 2017, PloS one.

[33]  K. Seppi,et al.  Magnetic resonance imaging for the diagnosis of Parkinson’s disease , 2017, Journal of Neural Transmission.

[34]  C. Achat-Mendes,et al.  Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectator , 2017, Neural regeneration research.

[35]  Daniela Berg,et al.  Advances in markers of prodromal Parkinson disease , 2016, Nature Reviews Neurology.

[36]  B. Boeve,et al.  Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. , 2016, Brain : a journal of neurology.

[37]  Amanpreet Singh,et al.  A review of supervised machine learning algorithms , 2016, 2016 3rd International Conference on Computing for Sustainable Global Development (INDIACom).

[38]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[39]  Carlos Ortiz-de-Solorzano,et al.  Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[40]  R. Postuma,et al.  Parkinson risk in idiopathic REM sleep behavior disorder , 2015, Neurology.

[41]  R. Rosner.  Beck Depression Inventory (BDI) , 2015 .

[42]  Jeff H Duyn,et al.  The role of iron in brain ageing and neurodegenerative disorders , 2014, The Lancet Neurology.

[43]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[44]  W. Meissner.  When does Parkinson's disease begin? From prodromal disease to motor signs. , 2012, Revue neurologique.

[45]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[46]  D. Brooks.  Imaging Approaches to Parkinson Disease , 2010, Journal of Nuclear Medicine.

[47]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[48]  Alberto Albertini,et al.  Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease , 2008, Journal of neurochemistry.

[49]  Paolo Barone,et al.  International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study , 2006, Movement disorders : official journal of the Movement Disorder Society.

[50]  Johan Marinus,et al.  Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[51]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[52]  Thomas G. Dietterich.  Multiple Classifier Systems , 2000, Lecture Notes in Computer Science.

[53]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[54]  R. Doty,et al.  Internal consistency reliability of the fractionated and whole University of Pennsylvania Smell Identification Test , 1989, Perception & psychophysics.

[55]  P. Riederer,et al.  Time course of nigrostriatal degeneration in parkinson's disease , 1976, Journal of Neural Transmission.

[56]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[57]  Robert M. Haralick,et al.  Textural Features for Image Classification , 1973, IEEE Trans. Syst. Man Cybern..

[58]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[59]  F. Carrillo,et al.  [Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane]. , 2013, Revista espanola de medicina nuclear e imagen molecular.

[60]  Teresa Foo,et al.  : SYSTEMATIC LITERATURE REVIEW , 2004 .

[61]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .